NCT06720233View on ClinicalTrials.gov

Efficacy and Safety Study of SAL-0951 in the Treatment of Renal Anemia in Patients Receiving Peritoneal Dialysis

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 22, 2002

Primary Completion Date

October 18, 2024

Study Completion Date

October 28, 2024

Conditions

Anemia

Interventions

DRUG

SAL-0951 tablets

initial phase：4mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks

Trial Locations (1)

510062

The First Affiliated Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors

lead

Shenzhen Salubris Pharmaceuticals Co., Ltd.

INDUSTRY

NCT06720233 - Efficacy and Safety Study of SAL-0951 in the Treatment of Renal Anemia in Patients Receiving Peritoneal Dialysis | Biotech Hunter | Biotech Hunter